Dr. Rosenberg is a highly experienced biotechnology veteran with over 30 years’ experience in the development of therapeutic agents to treat a variety of human diseases.  As a scientist, engineer, and executive, he has played a key role in the development of several important commercially approved therapeutics including AdcetrisTM,AvonexTM, AngiomaxTM, ForteoTM and TrodelvyTM.  Dr. Rosenberg has a D.Sc (1989) in Chemical Engineering from Washington University and previously worked at Invitron, Biogen, Eli Lilly, Seattle Genetics, and Immunomedics in positions of increasing responsibility.